{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.7","upperLimit":"94.7","value":"60.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The proportion of subjects evaluated as response \\[sCR + CR + very good partial response (VGPR) + Partial Response (PR)\\] was calculated.\n\nVGPR (IMWG): Serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or greater reduction in serum M-protein plus urine M-protein level \\<100mg per 24 h\n\nPR (IMWG): ≥50% reduction of serum M-protein and reduction in 24 h urinary M-protein by ≥90% or to \\<200mg per 24 h","dispersionType":"95% Confidence Interval","groups":[{"description":"SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible. Prednisolone (60 mg/m2/day) will be administered orally for 4 consecutive days and the course will be observed for the next 24 days.","id":"OG000","title":"SyB L-0501 + Prednisolone"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 36 weeks","title":"Response Rate (Based on the IMWG Criteria)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}